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1. Introduction 
Human immunodeficiency virus (HIV-1) currently infects 33.3 million people globally. In 
2009, 1.8 million people died from acquired immunodeficiency syndrome (AIDS) marking a 
decline in AIDS deaths by 19% since 1999, the estimated peak of the pandemic. This is 
largely due to the introduction of combination antiretroviral therapy (ART) in 1996 and its 
expanding access in recent years. However, despite continued efforts to improve ART 
availability worldwide, only 5 of the estimated 15 million people living with HIV-1 in low- 
and middle-income countries have access (UNAIDS, 2010). Furthermore, the number of new 
infections continues to outpace the number of people being put on ART each day. ART is 
costly, and places a formidable financial burden on healthcare services. This in turn 
compromises efforts for universal access.  
Combination ART has made a significant impact on HIV-1 morbidity and mortality 
(Vittinghoff et al., 1999, Palella et al., 2006) and represents the ‘gold standard’ for HIV-1 
treatment. Despite early optimism that combination ART could potentially eradicate 
infection (Perelson et al., 1996, Ho, 1997), it has since become clear that virus invariably 
returns if ART is stopped. As a result, ART remains a daily lifelong treatment requiring a 
high level of compliance to avoid the development of (multi) drug resistance.  
Where ART is available, the diagnosis ‘AIDS’ becomes less frequent, and HIV-1 infection 
may no longer be considered a irrevocable terminal disease but rather a chronic manageable 
infection. However, recent studies have observed that ART does not restore life expectancy 
completely (Neuhaus et al., 2010a; The Antiretroviral Therapy Cohort, 2008). Furthermore, 
as those living with HIV-1 do become older, age-related toxicities emerge (Powderly, 2007, 
2010) as well as other ART co-morbidities such as increased risk of cardiovascular disease, 
metabolic disorders, neurocognitive abnormalities, liver and renal disease, bone disorders, 
malignancy and frailty (Deeks & Phillips, 2009).  
Untreated HIV-1 infection is characterised by a substantial depletion of CD4+ T-cells in the 
mucosa as well as a gradual progressive decline of CD4+ T-cells in peripheral blood. When 
CD4+ T-cell levels in peripheral blood fall below 200 cells/mm3, immune competence is 
reduced leading to susceptibility to opportunistic infections and conditions that characterise 
AIDS as well as significant increases in viral load (Levy, 2007). It is primarily the level of 
CD4+ T-cells in peripheral blood that determines the requirement for ART (Panel on 
Antiretroviral Guidelines for Adults and Adolescents, 2011).  
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In recent years it has become apparent that disease progression in HIV-1 infection is not 
simply due to a loss of CD4+ T-cells as a result of chronic cytopathic viral infection. Instead, 
HIV-1 infection is accompanied by a progressive generalised immune activation (Neuhaus et 
al., 2010b; Kuller et al., 2008). Indeed, expression of the activation marker CD38 particularly on 
CD8+ T-cells has been found to be more predictive of disease progression than viral load 
(Giorgi et al., 1993; Hazenberg et al., 2003). Although immune activation may be reduced on 
effective ART, it is not completely absent but remains higher than in uninfected individuals. 
This may in part explain the loss and/or lack of optimal gain in CD4+ T-cell counts despite 
effective viral suppression below the level of detection (Hunt et al., 2003). It is intriguing that a 
similar immune activation is also observed in rhesus  macaques infected with simian 
immunodeficiency virus (SIVsmm or SIVagm) but not in the natural host for these viruses, the 
sooty mangabey and African green monkey respectively, despite high viral loads (Silvestri et 
al., 2003). Furthermore, HIV-2 in contrast to HIV-1, is associated with slower disease 
progression and lower levels of immune activation (Sousa et al., 2002).  
The underlying causes of the generalised immune activation associated with HIV-1 infection 
are presently not fully understood, but are probably associated with multiple mechanisms. 
These may include reactivation of latent viruses during HIV-1 infection, such as 
cytomegalovirus (CMV) or Epstein-Barr virus (EBV). The most widely considered 
mechanism is based on the significant depletion of CD4+ T-cells in the mucosa leading to a 
disruption of the gut lining and translocation of microbial flora to the systemic immune 
system (Brenchley et al., 2006). HIV-1 is known to incorporate host human leukocyte 
antigens (HLA) into its envelope during budding, that may play a role in immune 
activation. Furthermore, the conserved C5 region of gp120 may also be involved in immune 
activation (Cadogan & Dalgleish, 2008) by virtue of similarity with the peptide binding 
domains of HLA molecules. This region of gp120 has been shown to bind peptide and 
promote activation of antigen-specific T-cell clones (Sheikh et al., 2000). 
A small percent (<5%) of individuals have been found to control HIV-1 infection for long 
periods in the absence of ART. Virus levels, although very low – are never eliminated in 
these individuals (Hunt et al., 2011). These elite and viraemic controllers (that have a low 
viral load) have been shown to have narrow cell-mediated immune responses preferentially 
targeting Gag, and lower immune activation (Rosenberg et al., 1997; Zuniga et al., 2006; 
Walker, 2007; Saez-Cirion et al., 2007; Binley et al., 1997; Kiepiela et al., 2007). The fact that 
some individuals can control HIV-1 viraemia suggests that long-term immunological control 
of HIV-1 infection is possible. This therefore provides credence to the concept of therapeutic 
vaccination as a means to confer relevant immune stimulation that can ultimately lead to a 
sustained virological response, emulating a long-term nonprogressor status where the risk 
of virus transmission is reduced. As a result, more focus will need to be directed to 
understanding the mechanism(s) behind the control of HIV-1 in elite and viraemic 
controllers (Autran et al., 2011).  
Long-term control of HIV-1 infection in the absence of ART forms the basis for the term 
‘functional cure’ where virus and immune activation levels become equivalent to that found in 
elite controllers or natural virus suppressors (Jeffries, 2010). In contrast, a ‘sterilising cure’ relates 
to HIV-1 eradication, that is, the permanent removal of the HIV-1 by the complete elimination of 
viral reservoirs. The eradication concept has been inspired by ‘The Berlin Patient’ who received a 
bone marrow transplant from a donor that had the CCR5 32 mutation rendering the cells 
resistant to virus strains using this co-receptor for infection (Hütter et al., 2009). The Berlin patient 
has remained virus-free for four years to date (Allers et al., 2011).  
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Therapeutic vaccines have the advantage of being able to penetrate sanctuary sites less well 
accessed by ART such as lymphoid tissue (Pantaleo et al., 1991; Fox et al., 1991) and the 
central nervous system (Alexaki et al., 2008), that represent regions for viral persistence. This 
relates to therapeutic interventions targeting both the virus itself as well as HIV-associated 
immune activation. This chapter will discuss the potential contribution of therapeutic 
vaccination to achieve a functional cure for HIV-1 infection.  
2. HIV-1 persistence in reservoirs 
The failure of ART to eradicate HIV-1 infection lies in the observation that HIV-1 remains 
quiescent in latent reservoirs. Latently infected resting CD4+ cells (either naive or long lived 
memory cells) carry transcriptionally silent HIV-1 and represent the predominant reservoir 
of HIV-1 infection. Other cells may also act as reservoirs (Reviewed in Alexaki et al., 2008) 
such as macrophages, dendritic cells and astrocytes (where HIV-1 infection occurs via a 
CD4-independent mechanism). It is these latent reservoirs that represent the major challenge 
to eradication of HIV-1 infection. More than 80% of individuals on suppressive ART have 
persistent viraemia below the level of detection (Maldarelli et al., 2007). This low level 
viraemia is not reduced further despite ART intensification (Dinoso et al., 2009) supporting 
the concept that HIV-1 rebounds on ART cessation from the rapid reactivation of virus from 
latently infected cells rather than from continuous ongoing low level replication (Joos et al., 
2008). Long lived memory cells comprise approximately 1 cell per million with an extremely 
low decay rate explaining why 73 years is required to eliminate HIV-1 from infected 
individuals (Finzi et al., 1999, Siliciano, 2010). 
It is clear that to achieve a functional cure, therapeutic vaccination will need to induce not 
only effective antigen-specific immune responses but also combat the generalised immune 
activation induced by HIV-1.  
3. The concept of a functional cure  
The ultimate aim of a functional cure for HIV-1 infection is to induce long-term remission by 
depleting virus reservoirs to such an extent that a ‘controller’ status is achieved. In this way 
virus is maintained at low levels for long periods of time in the absence of ART, equivalent 
to that observed in known HIV-1 controllers (Lambotte et al., 2005) natural virus 
suppressors (Sajadi et al., 2007) and elite controllers (Deeks & Walker, 2007). This concept 
can be compared to achieving a sustained virological response for hepatitis C virus (HCV) 
infection following interferon/ribavirin treatment. If a sustained virological response is 
observed for HCV (undetectable virus for at least 6 months), the patient is considered cured. 
The potential for curing HCV infection is theoretically greater than for HIV-1 since HCV, a 
separate genus Hepacivirus within the virus family Flaviviridae, replicates solely in the 
cytoplasm of infected cells. As such, on cell division, the virus may remain in only one of the 
daughter cells. In contrast, HIV-1 is a retrovirus that integrates into the host genome and as 
such, on cell division will be automatically present in both daughter cells.  
A sustained virological response for HIV-1 could be envisaged as either: 
a. Indefinite virus control below the limits of detection (<50 copies HIV-1 RNA/ml) 
(equivalent to a sterilising cure/eradication).  
b. Long-term low level virus replication, as for a natural virus suppressor or long-term 
non progressor, with concomitant low levels of immune activation (equivalent to a 
functional cure).  
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Approaches towards eradication include attempts to purge reservoirs by selective activation 
of latently infected cells (such as memory cells) in the presence of ART such that released 
virus may not infect and replicate in neighbouring cells (Richman et al., 2009). Agents 
include histone deacetylase inhibitors, cytokines, such as IL-2 and IL-7, as well as bryostatin, 
the protein kinase C activator (Kovochich et al., 2011). However, such interventions may 
also be associated with side effects, resistance and high cost. 
Maintaining HIV-1-infected cells in a continuously latent (transcriptionally silent) state, akin 
to true latency characteristic of herpesviruses, represents the opposite extreme that has 
received less attention. HIV-1 is produced from activated CD4+ T-cells. At present it is not 
clear how HIV-1 can be maintained transcriptionally silent whilst still allowing for the CD4+ 
T-cell activation required to mount an immune response.  
3.1 Functional cure and treatment interruption 
In order to demonstrate a sustained virological response (functional cure) for patients that 
are well controlled on ART, treatment will ultimately need to be stopped in order to show 
that virus levels remain controlled (low/undetectable).  
Treatment interruption has been intensely investigated in the past as a means to overcome 
the limitations of lifelong ART which include side effects, drug resistance and high cost. 
Today, treatment interruption per se, is viewed with scepticism due to safety concerns 
arising from the SMART study, the largest treatment interruption study to date (El-Sadr et 
al., 2006). In the SMART study and numerous previous smaller studies, ART was 
interrupted without any additional immunological support. Treatment interruption in the 
SMART study was CD4-guided, where ART was discontinued when CD4 levels rose above 
350 cells/mm3 and resumed if CD4 counts fell below 250 cells/mm3. However, the study 
was prematurely halted since patients in the treatment conservation group (treatment 
interruption) experienced greater side effects and adverse events than those in the 
continuous ART arm. The SMART study therefore concluded that treatment interruption 
was not safe and that ART should remain a continuous life-long treatment. These safety 
concerns have affected the design of all treatment interruption trials including those for 
therapeutic vaccines. Interestingly, a more recent large study of the Swiss Cohort, has 
suggested that treatment interruption of up to six months can be safely tolerated 
particularly if patients are well monitored (Kauffman et al., 2011).  
Earlier clinical studies have shown that upon cessation of ART, and in the absence of 
therapeutic immunisation, CD4+ T-cell counts and virus load rebound to preART levels (i.e. 
the preART set point) (Oxenius et al., 2002a; Wit et al., 2005; Oxenius et al., 2002b; Mata et 
al., 2005). However, not all patients have available preART viral load information and 
therefore efforts have been made to identify alternate markers that may predict where the 
viral load may settle on treatment interruption in the absence of any other intervention. This 
is necessary in order to determine whether an intervention has lowered the viral load set 
point in a subject. Proviral DNA levels at baseline have been shown to correlate with the 
preART viral load, (Yerly et al., 2005), however, this approach will require further validation 
before it can be taken in to routine use. Until alternative markers are available, preART RNA 
values will remain the best predictor of the viral load set point that may be obtained on 
treatment interruption in the absence of therapeutic immunisation. Consequently, the effect 
of different therapeutic interventions on the viral load will therefore be compared to the 
preART values.  
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CD4+ T-cell counts represent the major parameter that determines the need for ART 
initiation. For this reason, earlier efforts within therapeutic vaccination aimed to 
improve CD4+ T-cell counts in order to slow disease progression. However, in light of 
the SILCAAT and ESPRIT studies that focused on improving CD4+ T-cell counts using 
IL-2 (which provides nonspecific immune stimulation unlike a therapeutic vaccine that 
is antigen-specific), the conclusion was that improving CD4 counts per se was not 
associated with clinical benefit (INSIGHT-ESPRIT and SILCAAT Study groups, 2009). 
Consequently, reducing viral load now represents the unequivocal major endpoint for 
any therapeutic vaccine or intervention aimed at effecting a functional cure or 
ultimately eradication.  
The current scepticism regarding treatment interruption means that inclusion criteria for 
patients in such studies will take in to consideration both preART and nadir (lowest ever) 
CD4+ T-cell counts since this has been shown to be a critical parameter in determining the 
outcome of treatment interruption (Willberg & Nixon, 2007). In subjects with low CD4+ T-
cells nadir (200-250 cells/mm3), CD4+ T-cell levels fall rapidly on treatment interruption 
requiring earlier re-initiation of ART (Toulson et al., 2005). Patients selected may therefore 
be relatively newly infected and have robust preART CD4+ T-cell levels and less well 
established viral reservoirs.  
3.1.1 Functional cure scenario 1: Long lasting remission on ART interruption 
One approach towards a functional cure could involve therapeutic vaccination in 
combination with ART followed by treatment interruption with the aim of providing long 
lasting sustained virological suppression. The advantage of immunising individuals in the 
presence of ART is that patients have usually regained CD4+ T-cell counts, including naive 
CD4+ T-cells that can be stimulated to target HIV-1. Furthermore, virus replication is 
controlled allowing for immunisation in the absence of circulating virus. The immunisation 
itself will provide some immune activation as CD4+ T-cells harbouring virus become 
activated leading to a virus burst which would nevertheless be contained by ART. It would 
therefore be important to allow for vaccine-induced immune activation to subside before 
stopping ART. Antigen-specific therapeutic vaccines inducing cell-mediated immune 
responses against gene products from multiply spliced RNA such as Tat may function in the 
presence of ART and remove infected cells. This is because these early gene products are not 
targeted by current antiretroviral therapy. Furthermore, Tat expression is not dependent on 
the activation state of the infected cell and is therefore also synthesized in quiescent T-cells 
in the absence of virus replication (Wu & Marsh, 2001). In contrast, for therapeutic vaccines 
targeting products requiring the expression of structural genes such as Gag and Env, ART 
would need to be stopped in order for the immune system to identify HIV-1 infected cells 
expressing these antigens.   
Therapeutic vaccination using antigen-specific immune stimulation could be combined with 
other interventions to provide a long-lasting reduction of HIV-1-associated generalised 
immune activation and consequently reduce the level of viral rebound even further. The aim 
would be that when patients are removed from ART, CD4+ T-cell counts would remain 
sustained and a virus set point would be established at a level compatible with a long-term 
non-progressor, or elite controller for a significant period of time (Figure 1). The therapeutic 
vaccine may also attenuate the height of the initial peak rebound so that it does not 
necessarily overshoot the preART value. This scenario may be most beneficial for newly 
infected subjects that have robust CD4 T-cell counts. 
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Stippled line at 350 indicates CD4 count below which ART should be initiated. Thick solid line: CD4 
count. Thin line: viral load (VL). Dashed line: PreART viral load  
Fig. 1. Scenario 1: Therapeutic vaccination in combination with ART leading to sustained 
virological response (long-lasting remission). Viral rebound may not necessarily overshoot 
the preART viral load. CD4+ T-cell levels would remain above the level of 350 cells/mm3 
that necessitates a return to ART according to current guidelines 
3.1.2 Functional cure scenario 2: Remission following intermittent ART 
It is possible that on treatment interruption as in scenario 1, viral load levels may stabilize at 
a lower set point, but not sufficiently low to be compatible with an HIV controller. This may 
be the case for individuals that started ART later on in disease course, where the number of 
viral reservoirs is greater, and the CD4+ T-cell nadir lower. To address this, therapeutic 
vaccination may be used to allow ART to become safely intermittent and where the viral set 
point may be sequentially reduced following multiple cycles of ART and booster 
immunisations with the therapeutic vaccine (Figure 2). In such a scenario, due to the safety 
concerns, the duration of the ART-free period should not exceed the 6 month time period 
shown to be safe in the Swiss cohort study (Kauffman et al., 2011). This approach of 
intermittent ART in combination with therapeutic immunisation and booster immunisations 
has not been investigated to date and may be viewed with scepticism due to the safety 
concerns arising from the SMART study. However, the underlying basis for the SMART 
study, i.e. a need to combat ART side effects, drug resistance and high cost remain relevant 
issues that need to be resolved.  
Similarly to scenario 1, therapeutic vaccination may also attenuate the size of the initial peak 
of rebound during the first treatment interruption allowing the set point to establish below 
the preART level. Following subsequent booster immunisations on ART in this scenario, as 
the viral load set point is lowered, CD4+ T-cell decline would also become less marked and 
would ultimately stabilise above the level necessitating ART (350 cells/mm3).  
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Stippled line at 350 indicates CD4 count below which ART should be initiated. Thick solid line: CD4 
count. Thin line: viral load (VL). Dashed line: PreART viral load 
Fig. 2. Scenario 2: Functional cure over time: intermittent ART supported by therapeutic 
vaccination, where viral rebound achieves a lower set point for each successive treatment 
interruption with a concomitant slower CD4+ T-cell decline over time 
Any therapeutic vaccination approach involving treatment interruption involves concerns 
that viral reservoirs would become repopulated. It is interesting to note that viral 
reservoirs are also repopulated in elite controller patients since they never manage to 
eliminate their virus despite maintaining a viral set point below the level of detection 
(Hunt et al., 2011).  
3.1.3 Functional cure scenario 3: On continuous ART 
Although potentially applicable to all patient categories, this third scenario for achieving a 
functional cure on continuous ART may be particularly suited for subjects where treatment 
interruption is not considered a viable option due to poor CD4+ T-cell reconstitution on 
ART, low CD4+ T-cell nadir or a very high preART viral load set point. This approach could 
involve combining continuous ART with therapeutic vaccination and reservoir purging 
agents (Figure 3).  
In this scenario, subjects would be maintained on continuous ART. Therapeutic vaccination 
would be carried out in the presence of ART as in scenarios 1 and 2 with the aim of 
generating more effective responses to HIV-1. However, instead of removing patients from 
ART as in scenarios 1 and 2, reservoir purging agents would be used to reverse latency and 
allow for the expression of viral genes. Viral replication and spread would be hindered due 
to the presence of ART. Expression of viral genes would render infected cells ‘visible’ to the 
immune system allowing for their removal as a consequence of the improved immune 
responses resulting from therapeutic immunisation. However, to show ultimately that viral 
reservoirs have been reduced significantly or even fully depleted, subjects will need to be 
removed from ART. 
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Stippled line at 350 indicates CD4 count below which ART should be initiated. Thick solid line: CD4 
count. Thin line: viral reservoirs  
Fig. 3. Scenario 3: Subjects remain on continuous ART. Therapeutic vaccination takes place 
in the presence of ART and the immune responses generated can remove infected cells that 
release virus following the use of reservoir purging agents. This procedure may need to be 
repeated to gradually remove virus reservoirs over time 
3.2 Functional cure and treatment naive patients 
Therapeutic vaccination of individuals that are treatment naive would be an attractive 
proposition in regions where ART availability is incomplete and where the financial burden 
to sustain life long treatment is greatest. In this case, subjects would be immunised in the 
presence of circulating virus to improve and direct immune responses to important epitopes 
such that viral load is decreased, CD4+ T-cell numbers have the potential to increase and the 
initiation of treatment delayed. However, therapeutic vaccination itself may result in a 
transient immune activation that could result in the seeding of further reservoirs with 
functional and ‘fit’ (replication competent) virus. 
Treatment naive individuals currently represent a study population where the effects of 
therapeutic vaccination on viral load and CD4+ T-cell counts can be readily observed. 
However, clinical trials involving treatment naive subjects will likely involve enrolment of 
patients that are early in disease course and where ART is not yet indicated. Such patients 
would likely have robust CD4+ T-cell counts and viral loads below 100 000 copies/ml. It is 
likely that viral reservoirs in these patients would be less well established. The more robust 
the CD4+ T-cell count, the more likely that the patient may provide an immunological 
response to the therapeutic vaccine.  
4. Approaches to therapeutic vaccination in clinical development 
A number of different approaches to HIV-1 therapeutic vaccination are currently in clinical 
development, although not necessarily at this point in time directly aiming to achieve a 
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functional cure (Tables 1-3). The majority of products aim to induce T-cell immunity 
whereas a minority aim to induce antibody responses to specific viral antigens.  
The viral antigens used as therapeutic vaccine candidates include peptides, polypeptides, 
fusion proteins, recombinant proteins, DNA, RNA either alone or with viral vectors such as 
poxviruses or adenoviruses, as well as inactivated autologous virus. These antigens can be 
injected directly or via ex vivo bombardment of autologous dendritic cells that are re-infused 
into the patient. The overall objective of therapeutic vaccine candidates is to reduce viral 
load, although some also aim to concurrently sustain CD4+ T-cell counts upon ART 
interruption. 
The potency of ex vivo stimulation of dendritic cells with inactivated autologous virus was 
first appreciated following the original studies by Lu et al., (2004) and Garcia et al., (2005) 
where subjects experienced a significant although transient reduction of viral load. Such 
approaches require access to autologous virus prior to ART initiation either for purification 
and inactivation or use as the basis for amplification of viral genes. This approach requires 
access to advanced technology and may require intermittent boosting to maintain the effect. 
Therapeutic vaccines are also being developed that aim to target dendritic cells in situ. This 
usually involves intradermal administration. Since intradermal injection requires trained 
personnel, alternative approaches are being developed to target dendritic cells such as 
topical patches/plasters. 
 
Company Product Clinical phase Technology  
Argos 
Therapeutics 
AGS-004 II 
n=34 
NCT00672191 
Autologous DCs co-electroporated with 
amplified in vitro transcribed RNA 
encoding CD40L and autologous HIV-1 
antigens derived from the patient’s own 
plasma taken immediately prior to the 
initiation of ART. 
Baylor 
University/ 
ANRS 
DC 
Vaccine 
I 
n=19 
NCT00796770 
DALIA study: Ex vivo administration of 
Lipopeptides to Nef, Gag and Env to DCs 
followed by reinfusion to patient  
Bionor 
Pharma 
Vacc-4x IIb 
n=137 
NCT00659789 
Peptides to conserved domains of HIV p24 
injected intradermally with GM-CSF.  
Genetic 
Immunity 
LC002 II 
n=16 
NCT00918840 
Clade  B DNA in nanoparticles and 
delivered to DCs in a patch (Dermavir). 
NIAID/ 
Profectus 
Biosciences 
MRK Ad5 
HIV-1 gag 
II 
n=120 
NCT00080106 
Replication defective adenovirus vector 
carrying HIV-1 gag. 
Table 1. Therapeutic vaccine candidates immunising subjects on ART with a treatment 
interruption phase in the study. DC:dendritic cell, TI: treatment interruption. NCT provides 
the clinical trial identifier for trials listed on www.clinicaltrials.gov  
Viral vectors derived from adenoviruses or poxviruses have also been extensively used to 
deliver DNA-based vaccines most often in a prime boost strategy. For such approaches it 
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will likely be necessary to determine the serological status of vaccine recipients to the 
viruses that have been used as a basis for these vectors since prior immunity may negatively 
affect vaccine efficacy. Similarly, maintenance of vaccine effect may require boosting using a 
heterologous virus vector, to avoid inhibitory effects of prior vaccine-induced immunity to 
the original vector. 
Although the induction of neutralising antibodies remains the major goal for an effective 
preventative vaccine, therapeutic vaccines aim to induce antibody responses to other viral 
antigens such as the HIV-1 Tat protein. Earlier studies have shown that loss of antibody 
responses to Tat correlated with disease progression (van Baalen et al., 1997; Rezza et al., 
2005). Such a vaccine may also address pathogenic effects of Tat released from infected cells 
(Ensoli et al., 1993). 
 
Company Product Clinical 
phase 
Technology  
Imperial 
College 
GTU-
MultiHIV-B 
(FIT06) 
I 
n=30 
NCT01130376 
DNA plasmid. Intradermal injections in 
combination with GM-CSF and IL-2 as 
well as a growth hormone. 
Univ. Oxford 
Med Research 
Council. 
MVA.HIVco
nsv 
I 
n=20 
NCT01024842 
MVA vector encoding a DNA that 
carries conserved domains in Gag, Vif, 
Pol, Env.  
University 
Pennsylvania
/ 
Drexel 
University 
PENNVAX 
B,GENEVA
X IL-12-
4532, 
pIL15EAM 
I 
n=38 
NCT00775424 
PENNVAX-B is a DNA vaccine 
encodes  synthetic HIV-1 envelope 
protein, Gag and Pol. GENEVAX and 
pIL15 are DNA adjuvants (IL-12 and 
IL-15)  
Massachusett
s General 
Hospital 
DNA I 
n=21 
NCT00833781 
Dendritic cells transfected with vectors 
encoding consensus (clade B) HIV Gag 
and Nef mRNA. 
NIAID HIV  
Antigens & 
IL-12 
I 
n=60 
NCT01266616 
Plasmid DNA with IL-12 to enhance 
the response.  
Table 2. Therapeutic vaccine candidates in clinical development where therapeutic 
vaccination occurs in the presence of continuous ART. DC: dendritic cell. NCT provides the 
clinical trial identifier for trials listed on www.clinicaltrials.gov  
5. The challenges facing therapeutic vaccination 
No preventative vaccine has yet been developed for HIV-1 infection. This is despite intense 
efforts since the virus was first isolated in 1983 (Barre-Sinoussi et al., 1983). The challenges 
faced by preventative and therapeutic vaccines are similar in that HIV-1 shows extensive 
genetic variation and a propensity for immune escape. Furthermore, human populations are 
also varied and this is characterised by a variety of human leukocyte antigens (HLA). HLA 
function to present HIV-1 epitopes at the surface of infected cells to allow for recognition 
and removal by cytotoxic T-lymphocytes. The association of certain HLA with virus control 
(e.g. HLA-B57) and disease progression (e.g. B35) has recently been highlighted 
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(International HIV Controllers Study Study, 2010). However these HLA alleles are not 
present in a large proportion of individuals. It has been suggested that patients in clinical 
studies should be HLA tested to help explain and understand the results (Li et al., 2011).  
One salient difference between the preventative and therapeutic vaccines lies in their 
objectives. At present it is considered remote that a vaccine can be developed that will yield 
sterilising immunity and complete protection from HIV-1 infection. For this reason, the 
objective of a preventative vaccine is now to prevent infection as far as is possible, and should 
infection occur the immune system will be sufficiently primed to ensure that the disease 
course is milder (Johnston & Fauci, 2007). This was the aim of the STEP trial, which used an 
adenovirus vector. However, unexpectedly, prior exposure to adenovirus infection resulted in 
greater susceptibility to HIV-1 infection in study participants (Buchbinder et al., 2008). 
 
Company Product Clinical phase Technology 
Genetic 
Immunity 
LC002 II 
n=36 
NCT00711230 
Clade  B DNA incorporated into 
nanoparticles and delivered to DCs 
in a patch (Dermavir). 
SEEK 
(previously 
PepTcell) 
HIV-v I 
n=55 
NCT01071031 
Mixture of polypeptide T-cell 
epitope sequences to conserved 
domains of HIV (internal proteins). 
Single subcutaneous injection  
Statens 
seruminstitutt, 
DK, EU clinical 
trials partnership 
AFO-18 I 
n=20 
NCT01141205 
Peptides representing 3 CD4 and 
17 CD8 minimal HIV epitopes. 
Adjuvant CAF01.  
Thymon TUTI-16 I/II 
n=24 
NCT00848211 
Tat Lipopeptide.  
Subcutaneous injection, acts as 
own adjuvant. 
FIT Biotech FIT06 
(GTU-
MultiHIV-B) 
II 
n=60 
DNA plasmid using GTU® 
Technology patented by FIT 
Biotech (Gene Transport Unit). 
Gag, Rev, Nef, Tat. Clade B. 
Hospital Clinic of 
Barcelona 
DCV2 I/II 
n=60 
NCT00402142 
Autologous dendritic cell pulsed ex 
vivo with patient’s own virus.  
Istituto Superiore 
di Sanita 
ISS T003  II 
n= 160 
NCT01029548 
Inactivated Tat protein injected 
intradermally (i.d.) to induce 
antibodies to Tat. This study is an 
observational cohort.  
Table 3. Therapeutic vaccine candidates in clinical development immunising subjects that 
are treatment naive. 
6. Conclusion 
The complexity of HIV-1 infection represents a challenge to achieving a functional cure or 
ultimately eradication of infection. A number of scenarios have been suggested in this 
chapter where therapeutic vaccination is combined with ART and also potentially with virus 
www.intechopen.com
 
Recent Translational Research in HIV/AIDS 
 
504 
purging agents. At present it is unlikely that any one scenario will suit all purposes, indeed, 
the choice of approach will likely depend upon the availability of ART, how far advanced 
the infection is on diagnosis and when during the disease course ART was initiated since 
these considerations will influence the size of viral reservoir.  
It is unlikely that there will ever be a single product that will either prevent HIV-1 infection 
completely or eradicate HIV-1 infection. Therefore, combinations may be more appropriate. 
Harnessing the immune system is a rational approach to combine with ART bearing in mind 
that the immune system may penetrate regions of the body not reached by current therapy. 
Combination ART has been more successful than monotherapy. Similarly combining ART 
with therapeutic vaccination and/or virus purging agents will likely be more effective than 
any of these interventions on their own. The recent Thai study provides is an example where 
two preventative vaccine candidates that had not shown effect earlier, provided an improved 
response leading to a marginally significant effect when combined (Reks-Ngarm et al., 2009).  
Ultimately a therapeutic vaccine will need to confer effective immune responses in all 
individuals regardless whether they possess HLA compatible with virus control or not. It is 
therefore important that therapeutic vaccine candidates take into consideration genetic 
variation in both human and viral populations in order to be able to elicit the most effective 
responses leading to control of infection. Strictly, the term ‘functional cure’ can be 
considered misleading since virus is not completely removed from the body, but rather the 
patient experiences remission from symptoms. The term ‘functional control’ would 
therefore be more appropriate.  
Eradication approaches will require much research and development, where both novel and 
known compounds will be tested in new ways to determine a potential effect on eradication 
without incurring too many side effects. It may therefore take significant time before such 
products are available on the market. In contrast, a functional cure may be achievable in the 
shorter term and represent a more realistic goal since virus reduction has been shown for a 
number of therapeutic vaccine candidates. Approaches that aim to successfully combat HIV-1 
infection will need to address both the virus (virus-specific approaches including ART and 
therapeutic vaccines) as well as the generalized immune activation that drives the infection. 
It is likely that to achieve a functional cure, a combination of different interventions may 
ultimately be required.  
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